Trial · NCT00790907
Results by group46
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 46
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Composite of Major Bleeding, Minor Bleeding, or Major Vascular Access Site Complications During the Peri-PCI Period | OL Fondaparinux Background + Low Dose UFH During PCI | 48 | participants | ||
| Number of Participants With Composite of Major Bleeding, Minor Bleeding, or Major Vascular Access Site Complications During the Peri-PCI Period | OL Fondaparinux Background + Standard Dose UFH During PCI | 58 | participants | ||
| Number of Participants With Composite of Major Bleeding During the Peri-PCI Period, With Death, MI, or TVR at Day 30 | OL Fondaparinux Background + Low Dose UFH During PCI | 59 | participants | ||
| Number of Participants With Composite of Major Bleeding During the Peri-PCI Period, With Death, MI, or TVR at Day 30 | OL Fondaparinux Background + Standard Dose UFH During PCI | 39 | participants | ||
| Number of Participants With Major Bleeding During the Peri-PCI Period | OL Fondaparinux Background + Low Dose UFH During PCI | 14 | participants | ||
| Number of Participants With Major Bleeding During the Peri-PCI Period | OL Fondaparinux Background + Standard Dose UFH During PCI | 12 | participants | ||
| Number of Participants With Minor Bleeding During the Peri-PCI Period | OL Fondaparinux Background + Low Dose UFH During PCI | 7 | participants | ||
| Number of Participants With Minor Bleeding During the Peri-PCI Period | OL Fondaparinux Background + Standard Dose UFH During PCI | 17 | participants | ||
| Number of Participants With Major Vascular Access Site Complications During the Peri-PCI Period | OL Fondaparinux Background + Low Dose UFH During PCI | 33 | participants | ||
| Number of Participants With Major Vascular Access Site Complications During the Peri-PCI Period | OL Fondaparinux Background + Standard Dose UFH During PCI | 43 | participants | ||
| Number of Participants With Major PCI-related Procedural Complications | OL Fondaparinux Background + Low Dose UFH During PCI | Abrupt Vessel Closure | 10 | participants | |
| Number of Participants With Major PCI-related Procedural Complications | OL Fondaparinux Background + Standard Dose UFH During PCI | Abrupt Vessel Closure | 17 | participants | |
| Number of Participants With Major PCI-related Procedural Complications | OL Fondaparinux Background + Low Dose UFH During PCI | New Angiographic Thrombus | 11 | participants | |
| Number of Participants With Major PCI-related Procedural Complications | OL Fondaparinux Background + Standard Dose UFH During PCI | New Angiographic Thrombus | 8 | participants | |
| Number of Participants With Major PCI-related Procedural Complications | OL Fondaparinux Background + Low Dose UFH During PCI | Suspected Catheter-related Thrombus | 4 | participants | |
| Number of Participants With Major PCI-related Procedural Complications | OL Fondaparinux Background + Standard Dose UFH During PCI | Suspected Catheter-related Thrombus | 3 | participants | |
| Number of Participants With Major PCI-related Procedural Complications | OL Fondaparinux Background + Low Dose UFH During PCI | Catheter-related Thrombus-Adjudicated | 4 | participants | |
| Number of Participants With Major PCI-related Procedural Complications | OL Fondaparinux Background + Standard Dose UFH During PCI | Catheter-related Thrombus-Adjudicated | 1 | participants | |
| Number of Participants With Major PCI-related Procedural Complications | OL Fondaparinux Background + Low Dose UFH During PCI | No-reflow Phenomenon | 20 | participants | |
| Number of Participants With Major PCI-related Procedural Complications | OL Fondaparinux Background + Standard Dose UFH During PCI | No-reflow Phenomenon | 22 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00790907/results